Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study-Reference-Cited by-同舟云学术

Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

Published:2022-02 Issue:1 Volume:20 Page:25-34
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Pinto Álvaro^ORCID,Reig Oscar^ORCID,Iglesias Clara^ORCID,Gallardo Enrique^ORCID,García-del Muro Xavier,Alonso Teresa,Anguera Georgia,Suárez Cristina,Muñoz-Langa José,Villalobos-León Laura^ORCID,Rodríguez-Sánchez Ángel,Lainez Nuria,Martínez-Ortega Esther,Campayo Marc,Velastegui Alejandro,Rodriguez-Vida Alejo,Villa-Guzmán José C.,Méndez-Vidal Maria J.,Rubio Gustavo,García Iciar,Capdevila Laia,Lambea Julio,Vázquez Sergio,Fernández Ovidio,Hernando-Polo Susana,Cerezo Sara,Santander Carmen,García-Marrero Rosa,Zambrana Francisco^ORCID,González-del Alba Aranzazu,Lazaro-Quintela Martin,Castellano Daniel,Chirivella Isabel^ORCID,Anido Urbano^ORCID,Viana Antonio,García Arancha,Sotelo Miguel,Arévalo María Garrido,García-Donas Jesús,Hernández Carolina,Bolós M. Victoria,Llinares Julia,Climent Miguel A.

Funder

Pfizer Ltd

Pfizer

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference38 articles.

1. Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma;Atkins;Cancer Treat Rev,2018

2. Nivolumab plus ipilimumab vs. sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

3. Avelumab plus Axitinib vs. sunitinib for advanced renal-cell carcinoma;Motzer;N Engl J Med,2019

4. Pembrolizumab plus Axitinib vs. sunitinib for advanced renal-cell carcinoma;Rini;N Engl J Med,2019

5. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy;Zarrabi;J Hematol Oncol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population;Future Oncology;2024-06-23

2. Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy;Cancer Research and Treatment;2023-04-15

3. Axitinib;Reactions Weekly;2022-05